MK-677 (Ibutamoren) for MMA and Combat Sports: A Women's Protocol Guide

What MK-677 Actually Does, and Why Female Fighters Are Using It

MK-677 stimulates growth hormone (GH) release and raises IGF-1 by mimicking ghrelin at the GHSR-1a receptor. Unlike injectable GH, it is taken by mouth, which is a major practical draw for athletes. For MMA and combat sports women, the appeal centers on three things: faster soft-tissue healing between hard training blocks, deeper slow-wave sleep for overnight recovery, and a possible neuroprotective effect after head impact.

A randomized, double-blind trial by Nass et al. (2008) in 65 healthy older adults showed that 25 mg daily for two years increased IGF-1 by roughly 40% above baseline while maintaining GH pulsatility within normal range. That trial enrolled both men and women, but the published sub-group analysis by sex is thin, meaning direct extrapolation to a 28-year-old female fighter requires caution.

Growth hormone itself is not a flat hormone. It is released in pulses, and those pulses are shaped by estrogen. Veldhuis et al. Documented that premenopausal women secrete more GH per burst than age-matched men, partly because estrogen amplifies pituitary somatotroph sensitivity. When you add a secretagogue like MK-677 on top of that, the combined GH exposure may be higher in a cycling woman than the male-derived trial data would predict. That means female fighters may need a lower starting dose, and monitoring IGF-1 labs becomes more important, not optional.

How the Menstrual Cycle Changes the Picture

Estrogen rises in the follicular phase and peaks around ovulation. GH secretion naturally rises with it. If you are taking MK-677 through a full cycle, your IGF-1 response will likely fluctuate with your estrogen level rather than staying flat. No published study has mapped MK-677 pharmacodynamics across the menstrual cycle in premenopausal women. This is an evidence gap you deserve to know about before starting.

Perimenopause and Post-Menopause Considerations

When ovarian estrogen production declines, GH pulsatility drops significantly. Giustina and Veldhuis (1998) showed that estrogen deficiency reduces mean 24-hour GH secretion by up to 30-50% in postmenopausal women. A postmenopausal female fighter or masters-division athlete who uses MK-677 may therefore see a more pronounced absolute IGF-1 rise than a younger premenopausal peer, which raises the importance of lab monitoring. If you are also using hormone therapy (HT), oral estrogen in particular further amplifies IGF-1 generation in the liver, so IGF-1 levels could rise more than expected.

The Evidence: What Studies Actually Show (and What They Don't)

The clinical trial record for MK-677 is actually one of the more solid ones in the secretagogue space, at least for certain endpoints. The problem for female combat athletes is that none of the trials were designed with you in mind.

Muscle and Body Composition

A 12-month RCT by Murphy et al. (2001) in 65 adults aged 60 to 81 found that 25 mg daily increased lean body mass by approximately 1.5 kg versus placebo, with no significant change in fat mass over the same period. The sample included women, but results were not stratified by sex in the primary publication.

For a fighter, lean mass retention during a caloric deficit before a weight cut matters enormously. MK-677 does not cause acute anabolism the way testosterone does. What it may do is reduce the lean tissue catabolism that happens when training load is high and calorie intake is controlled. That is a more modest and specific claim than "builds muscle," and it is the one better supported by the data.

Sleep Architecture

Copinschi et al. (1997) showed that a single dose of MK-677 in healthy young adults significantly increased slow-wave sleep duration. For combat athletes who accumulate physical and neurological stress from training, slow-wave sleep is when GH secretion naturally peaks and tissue repair is prioritized. This finding has been replicated in smaller studies and is one of the more consistent signals in the MK-677 literature.

Bone Density

Svensson et al. (1998) in healthy older adults showed increases in markers of bone turnover, particularly bone formation markers, over 12 months. For female combat athletes, bone stress injuries and stress fractures are real concerns, particularly in women with low energy availability or history of menstrual dysfunction. Whether MK-677 meaningfully reduces fracture risk in active women is unknown. No fracture-endpoint trial exists in this population.

Concussion and Neuroprotection

This is where the evidence becomes genuinely thin. Animal models show GH-axis stimulation supports neuroinflammation resolution and axonal repair after traumatic brain injury. The GH Research Society consensus statement (2010) acknowledged post-traumatic GH deficiency as a real clinical entity affecting up to 30% of TBI survivors, and replacement GH has shown cognitive benefit in those patients. Whether prophylactic or peri-injury elevation of IGF-1 via MK-677 in otherwise GH-sufficient athletes translates to brain protection is extrapolation, not established fact. Label it as such.

The three-tier evidence framework for female combat sports use:

| Endpoint | Evidence Level | Female-Specific Data | |---|---|---| | IGF-1 elevation | RCT (Level 1) | Thin; sex sub-groups rarely published | | Lean mass retention | RCT (Level 1) | Mixed-sex samples only | | Sleep quality | RCT (Level 1) | Not stratified by sex or cycle phase | | Bone turnover markers | RCT (Level 1) | Includes women 60+; no data in athletes | | Neuroprotection / concussion | Animal + mechanistic (Level 4) | No female-specific data | | Soft-tissue healing speed | Anecdotal practitioner experience (Level 5) | No RCT in any sex |

A Structured Protocol for Female Combat Athletes

This protocol reflects the available trial data and practitioner experience reported in the literature. It is not a prescription. Because MK-677 is not FDA-approved and is listed on the WADA Prohibited List, any use requires informed decision-making with a clinician who can monitor labs.

Starting Dose

Begin at 10 mg once daily, taken at bedtime to align the additional GH pulse with the natural nocturnal GH peak and to let sedating side effects (appetite spike, transient fatigue) occur during sleep. The 25 mg dose used in most trials may produce more pronounced water retention and appetite stimulation than many female fighters want, especially during a weight management phase.

If IGF-1 at 4 weeks is in the lower-normal range for your age (roughly 100-200 ng/mL for women aged 20-40 per IGF-1 reference intervals published by Bidlingmaier et al.), you can consider titrating to 15-20 mg.

Timing Within the Training Cycle

Use MK-677 during high-volume training blocks and recovery phases, not during active weight cuts. The compound raises appetite substantially and causes water retention via aldosterone-like effects, which works against the goal of making weight. A typical approach in practice:

• Weeks 1-10: 10-15 mg nightly during hard camp or off-season training
• Weeks 11-12 (weight cut window): Hold or discontinue
• Post-fight recovery week: Resume at 10 mg to support tissue repair
• Week 13 onward: 4-8 week break before reassessing

Cycle Length and Off Periods

Published trials ran up to 24 months continuously in elderly subjects. For healthy younger women, most experienced clinicians recommend 8-16 week on-cycles followed by 4-8 week breaks to allow the GH axis to maintain its own baseline pulsatility. Continuous use risks progressive IGF-1 elevation beyond the upper reference range, which is associated with insulin resistance and joint swelling.

Monitoring Labs

Minimum monitoring schedule for a female athlete on MK-677:

| Timepoint | Labs | |---|---| | Baseline | IGF-1, fasting glucose, HbA1c, TSH, LH/FSH, estradiol (day 3 if cycling), prolactin | | Week 4 | IGF-1, fasting glucose | | Week 8-10 | IGF-1, fasting glucose, HbA1c, lipid panel | | End of cycle | Full panel above, plus DEXA if bone health is a concern |

Prolactin is worth checking because elevated GH/IGF-1 can occasionally suppress LH pulsatility and alter cycle regularity. If your periods change within the first two months, get labs before continuing.

Insulin Sensitivity Monitoring

MK-677 causes a measurable reduction in insulin sensitivity. The Nass et al. (2008) trial found fasting glucose rose an average of 2-4 mg/dL and insulin levels increased in the MK-677 group versus placebo. For a woman with PCOS, prediabetes, or a family history of type 2 diabetes, this signal matters. If your fasting glucose rises above 100 mg/dL or your HbA1c climbs, the compound should be paused and discussed with your prescriber.

PCOS-Specific Note

Women with PCOS already have altered GH-IGF-1 axis function. Morales et al. (1996) showed that IGF-1 directly stimulates ovarian androgen production. Elevating IGF-1 pharmacologically in a woman with PCOS may worsen androgen excess, worsen acne, and potentially worsen anovulation. If you have PCOS, MK-677 requires careful monitoring of androgens (free testosterone, DHEAS) alongside the standard metabolic labs.

Pregnancy, Lactation, and Contraception

MK-677 is not safe to use during pregnancy. There are no human pregnancy safety data. Animal reproductive toxicology studies have not been published in peer-reviewed form, which means there is no reassuring safety signal, not a clean one. Given that MK-677 raises IGF-1, and given that IGF-1 is a known regulator of placental growth and fetal development (with excess associated with fetal overgrowth in conditions like gestational diabetes), theoretical fetal risk exists.

ACOG's guidance on sports supplements in pregnancy recommends avoiding any supplement without established human pregnancy safety data. MK-677 clearly falls into that category.

If you are trying to conceive: Stop MK-677 at least one full menstrual cycle, preferably two to three cycles, before attempting conception. There is no pharmacokinetic data on MK-677 clearance time in women, but its half-life is approximately 24 hours, suggesting it clears within days. The caution around trying to conceive is about axis normalization rather than drug persistence.

Lactation: No human milk transfer data exists. Given that GH axis peptides are generally large enough to be digested rather than absorbed intact, and that MK-677 is a small non-peptide molecule (MW ~624 g/mol), passive transfer into breast milk is theoretically possible. Until transfer studies are done, the precautionary recommendation is to avoid use while breastfeeding.

Contraception requirement: Because MK-677 is contraindicated in pregnancy and female fighters often have irregular cycles from training load, reliable contraception is recommended for any sexually active woman using this compound. Hormonal contraception may itself alter GH secretion and IGF-1 levels (oral contraceptives suppress IGF-1 via hepatic IGF-1 generation changes), which is another reason baseline and on-cycle IGF-1 monitoring matters.

Who This Protocol May Be Right For (and Who It Is Not)

Potentially Appropriate

• Premenopausal female combat athletes in good metabolic health (normal fasting glucose, no PCOS, regular periods) who are not pregnant or trying to conceive
• Masters-division fighters aged 35-50 who want to support recovery capacity and sleep quality during hard training
• Post-menopausal women who have completed childbearing and have confirmed normal fasting glucose and IGF-1, with ongoing clinician monitoring
• Women recovering from musculoskeletal injury during an off-season period where weight management is not an active goal

Not Appropriate

• Pregnant women or those trying to conceive
• Women who are breastfeeding
• Women with active PCOS without androgen monitoring in place
• Women with prediabetes, type 2 diabetes, or metabolic syndrome
• Competitive athletes subject to WADA or USADA testing. MK-677 has been on the WADA Prohibited List (S2, Peptide Hormones, Growth Factors, Related Substances) since 2020 and detection windows in urine are being actively extended

Side Effects Women Report More Than Men Do

Male-default trial reporting under-represents some of the side effects that female athletes flag in clinical practice.

Water retention and puffiness: Estrogen amplifies aldosterone sensitivity. Women on MK-677 during the luteal phase may find bloating and facial puffiness particularly pronounced in the week before their period, on top of the baseline retention MK-677 causes.

Appetite surge: The ghrelin-mimetic mechanism causes significant hunger, often hitting hardest in the first 2-3 weeks. For a fighter managing weight class, this requires planning. Eating a high-protein meal before bed when the compound is dosed can blunt the late-night hunger spike.

Transient elevated prolactin: Some women report galactorrhea or breast tenderness. Check prolactin at baseline and at 8 weeks. Persistent prolactin elevation warrants stopping the compound and ruling out other causes.

Joint swelling and carpal tunnel-like symptoms: IGF-1-driven fluid shifts can cause tingling or tightness in the hands and wrists, exactly the joints female fighters depend on for striking. This is dose-related and typically resolves by reducing dose or stopping.

Menstrual changes: No published data; purely clinical observation. Some women report shorter cycles or spotting in the first month. If this persists beyond cycle two, check LH, FSH, estradiol, prolactin, and IGF-1.

The Evidence Gap: What Hasn't Been Studied

Women have been historically under-represented in GH-secretagogue trials. The large MK-677 RCTs were conducted in elderly populations, obesity medicine, and sarcopenia research, all contexts where male subjects dominate or sex-disaggregated data is sparse.

Specific gaps for female combat athletes:

1. No RCT has tested MK-677 in premenopausal female athletes at any dose.
2. No pharmacokinetic study has measured MK-677 plasma levels across the menstrual cycle.
3. No study has measured IGF-1 response in women with PCOS versus ovulatory women at matched doses.
4. No concussion or TBI trial in female athletes has used MK-677 as an intervention.
5. No milk transfer or fetal safety study exists.

The absence of this data does not mean MK-677 is unsafe for women. It means decisions are being made without a complete evidence base. The GH Research Society has explicitly called for more sex-disaggregated reporting in GH-axis research. Until that data exists, using MK-677 as a female combat athlete means accepting that you are working from male-derived estimates adjusted by clinical judgment, not direct evidence.

Practical Week-by-Week Timeline of Expected Outcomes

| Week | What You May Notice | |---|---| | 1-2 | Increased sleep depth and more vivid dreams; appetite increase (strongest in this window) | | 3-4 | Mild water retention; some joint puffiness possible; IGF-1 begins rising toward new plateau | | 5-8 | Training soreness recovery may feel faster; sleep remains improved; appetite normalizes somewhat | | 8-10 | IGF-1 reaches approximate steady state; check labs at this point | | 12-16 | Most practitioners observe the clearest subjective recovery and body composition changes in this window | | After cycle | IGF-1 returns toward baseline within 2-4 weeks of stopping based on compound half-life |